Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 46 pages | ID: T32C09C0F7C3EN
Global Markets Direct

Abstracts

Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Asarina Pharma AB
Emalex Biosciences Inc
Evero Health Ltd
Noema Pharma AG
Octapharma AG
SOM Biotech SL
Tourette Syndrome - Drug Profiles
bevantolol - Drug Profile
Product Description
Mechanism Of Action
dronabinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
History of Events
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
NOE-105 - Drug Profile
Product Description
Mechanism Of Action
History of Events
sepranolone - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
Product Description
Mechanism Of Action
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 16, 2022: First patient in for landmark Tourette Syndrome study
Jan 18, 2022: SciSparc advances its phase IIb clinical trial in patients with Tourette syndrome with its proprietary drug candidate SCI-110
Dec 22, 2021: Asarina Pharma receives final approval for landmark phase IIa Tourette study
Dec 08, 2021: Noema Pharma hosting key opinion leader webinar on Stuttering
Nov 10, 2021: Paragon's portfolio company Emalex Biosciences announces positive topline results from phase 2b clinical study evaluating ecopipam for pediatric Tourette syndrome
Sep 16, 2021: Administrative backlog at public authority causes short-term delay in Tourette study
Aug 05, 2021: Noema Pharma initiates phase 2a Allevia study of PDE10A inhibitor NOE-105 in Tourette Syndrome
Jul 26, 2021: SciSparc announces updates regarding its phase IIb study in Tourette Syndrome
Jun 22, 2021: Emalex Biosciences announces completion of patient enrollment in phase 2b clinical trial evaluating Ecopipam (EBS-101) for pediatric patients with Tourette Syndrome
Jun 08, 2021: Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
May 19, 2021: Asarina Pharma receives approval of CTA for phase IIa Tourette study
Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
Feb 10, 2021: SciSparc engages Procaps for development and production of CannAmide and its SCI-110 product candidate
Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
Mar 24, 2020: Asarina Pharma to release historic Phase IIb PMDD data on schedule
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Tourette Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Tourette Syndrome - Pipeline by Asarina Pharma AB, 2022
Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2022
Tourette Syndrome - Pipeline by Evero Health Ltd, 2022
Tourette Syndrome - Pipeline by Noema Pharma AG, 2022
Tourette Syndrome - Pipeline by Octapharma AG, 2022
Tourette Syndrome - Pipeline by SOM Biotech SL, 2022
Tourette Syndrome - Dormant Projects, 2022
Tourette Syndrome - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Tourette Syndrome, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022